Cancer leads way to routine use of accelerated approval: Data Byte

Accelerated approval is becoming the de facto route for approvals of new molecular entities in cancer.

In three of the past five years, the number of new cancer drugs granted accelerated approval by FDA has outnumbered those given full approval. Halfway through this year, the count stood at eight accelerated to four standard approvals. ...